lung cancer
Rare lung cancer drug approved in Scotland
August 14, 2018Manufacturing and Production Cancer, SMC, Scotland, Scottish Medicines Consortium, approval, lung cancer
The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung …
Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer
July 27, 2018Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma
Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …
AstraZeneca chalks up double Japanese approval in lung and breast cancer
July 2, 2018Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma
It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …
Top Ten most popular articles on Pharmafile.com this week
June 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma
Summer seems to be in full swing as we reach the end of June, so it’s time to look back …
Roche’s Tecentriq combo extends life in untreated lung cancer
June 25, 2018Research and Development, Sales and Marketing Cancer, Roche, lung cancer, pharma, tecentriq
Roche has unveiled new data on the efficacy of Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the …
AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer
June 22, 2018Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma
In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …
BMS’ Opdivo becomes first immuno-oncology agent available in China
June 18, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma
Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …
Roche’s breast, lung cancer offerings fail to impress at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …
Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3
May 29, 2018Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …
AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer
May 25, 2018Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …
AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer
April 19, 2018Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma
AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …
Keytruda success continues, beating Opdivo in lung cancer survival
April 17, 2018Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …
Hanmi terminates lung cancer drug after being muscled out by AZ’s Tagrisso
April 13, 2018Medical Communications, Research and Development AstraZeneca, Cancer, Otila, Tagrisso, hanmi, lung cancer, pharma
South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it …
Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression
April 10, 2018Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …
Tecentriq third time lucky after NICE nod in lung cancer
April 9, 2018Sales and Marketing NICE, Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq
After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
